Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962913 | 0.73 | NPC1 (0.33) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL5165562 | 0.69 | GSK3A (0.73) | ALDH1A1LMNAMEN1KMT2AGSK3A | |
| SCHEMBL27802875 | 0.66 | ALDH1A1 (0.53) | ALDH1A1KDM4E | |
| SCHEMBL10928073 | 0.65 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AESR1 | |
| SCHEMBL3519506 | 0.65 | KMT2A (0.56) | ALDH1A1LMNAKMT2A | |
| SCHEMBL5982787 | 0.65 | ALDH1A1 (0.43) | ALDH1A1LMNAMEN1KMT2AGSK3A | |
| SCHEMBL12038001 | 0.65 | SMN1; SMN2 (0.44) | ALDH1A1LMNAMEN1KMT2AGSK3A | |
| SCHEMBL22800 | 0.64 | — | — | |
| SCHEMBL2824399 | 0.62 | CA12 (0.56) | ALDH1A1MEN1KMT2AGSK3AGSK3B | |
| SCHEMBL5613210 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170280-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250170279-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| US-20200397926-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2020-12-24 | — | — | US | claimed |
| EP-3744317-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Inno Medicine Co., Ltd. (CN) | 2020-12-02 | — | — | EP | claimed |
| EP-3610859-A1 | CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE | Beijing Inno Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-110536680-A | Dendritic nano-carrier delivery system, preparation method and use for targeted activation CD44 molecule | BEIJING INNO MEDICINE CO LTD | 2019-12-03 | — | — | CN | claimed |
| EP-2526973-B1 | X ray contrasting agent for post-mortem, experimental and diagnostic angiography | FORIM-X AG (CH) | 2017-06-21 | — | — | EP | claimed |
| US-20170066828-A1 | Humanized Anti-HLA-DR Antibodies | IMMUNOMEDICS, INC. | 2017-03-09 | — | — | US | claimed |
| US-20020044968-A1 | High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion | GENERAL MILLS, INC. | 2002-04-18 | — | — | US | claimed |
| WO-2002030394-A2 | MEDICINAL AEROSOL FORMULATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| JP-2002511777-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1119345-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-5693337-A | OIL IN WATER EMULSION CONTAINING DRUG, LECITHIN, CITRIC ACID, AND METHIONINE, PHENYLALANINE, SERINE, AND/OR HISTIDINE; SYNERGISTIC, STORAGE STABILITY | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-12-02 | — | — | US | claimed |
| EP-0700678-A1 | Stable lipid emulsion | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | CD44, LDLR, PLAUR | ALDH1A1 2288/4885LMNA 265/4885MEN1 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.